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I M M U N O L O G Y
Red blood cell–derived nanoerythrosome for antigen 
delivery with enhanced cancer immunotherapy
Xiao Han1*, Shufang Shen1*, Qin Fan1, Guojun Chen2, Edikan Archibong3, Gianpietro Dotti3, 
Zhuang Liu1†, Zhen Gu2,4†, Chao Wang1†
Erythrocytes or red blood cells (RBCs) represent a promising cell-mediated drug delivery platform due to their 
inherent biocompatibility. Here, we developed an antigen delivery system based on the nanoerythrosomes 
derived from RBCs, inspired by the splenic antigen-presenting cell targeting capacity of senescent RBCs. Tumor 
antigens were loaded onto the nanoerythrosomes by fusing tumor cell membrane–associated antigens with 
nanoerythrosomes. This tumor antigen–loaded nanoerythrosomes (nano-Ag@erythrosome) elicited antigen 
responses in vivo and, in combination with the anti–programmed death ligand 1 (PD-L1) blockade, inhibited the 
tumor growth in B16F10 and 4T1 tumor models. We also generated a tumor model showing that “personalized 
nano-Ag@erythrosomes” could be achieved by fusing RBCs and surgically removed tumors, which effectively 
reduced tumor recurrence and metastasis after surgery.
INTRODUCTION
Immune checkpoint blockade (ICB) therapy unleashes the patient’s 
immune system, resulting in the tumor regression of various types 
of cancer (1–4). However, the response rate remains low in several 
malignancies, and immune-related adverse events can occur after 
ICB therapy, indicating that this strategy requires improvements to 
maximize activity while reducing toxicity (5–9). The combination 
of ICB with other treatments has been demonstrated to improve 
the response rate (10–13). Among them, several clinical trials have 
verified that immune responses could be elicited in cancer patients 
by cancer vaccines (14–16), but the achievement of objective clinical 
responses remains challenging (17, 18). Possible reasons include 
the immunosuppressive nature of the tumor microenvironment 
[for example, a high level of programmed death ligand 1 (PD-L1) 
expression in tumor cells]. In addition, PD-L1 expression on antigen- 
presenting cells (APCs) failed to induce T cell proliferation and 
furthermore was able to induce T regulatory cells (19). Therefore, 
the combination of anti–PD-L1 (aPDL1) with cancer vaccine could 
be beneficial.
In addition, the inefficient delivery of tumor antigens to professional 
APCs in vivo (20) contributes to reducing the potency of cancer 
vaccines. Over the past few decades, various antigen delivery systems 
have been reported in animal models. Micro-/nanoformulations 
and macroscale biomaterials as effective antigen delivery tools and/or 
as adjuvants for improving immune response could generate ro-
bust antitumor immune response compared with free antigen 
(16, 21–27). However, many of them are synthetic materials and 
need chemical conjunction. The safety profile of such systems is 
often concerned regarding physiological interaction and metabolism 
for clinical practice.
Here, we report a combination of cancer vaccine based on the 
erythrocyte membrane and aPDL1 blockade. Because of their inherent 
biocompatibility, the red blood cells (RBCs) have been widely studied 
for drug delivery (28, 29). Notably, senescent or damaged RBCs are 
physiologically eliminated by scavenger cells, such as macrophages 
and dendritic cells (DCs) within the spleen (30, 31). Spleen is a critical 
secondary lymphoid organ in which B cells, T cells, natural killer 
(NK) cells, and APCs such as DCs are particularly abundant (23). 
We thus hypothesized that damaged RBC could be leveraged to 
deliver tumor-associated antigens (TAAs) to APCs in a critical 
secondary lymphoid organ. To this end, nanosized RBC–tumor 
membrane vesicles or nanoerythrosomes through sonication and 
membrane extrusion (32) were fused with the membrane of tumor 
cells to obtain nano-Ag@erythrosome (33). In vivo delivery of nano- 
Ag@erythrosome effectively reached splenic APCs and activates 
T cell immune responses. In mouse B16F10-Luc and 4T1 tumor 
models, the combination of nano-Ag@erythrosome and ICB caused 
tumor regression. Furthermore, “personalized vaccination” with nano- 
Ag@erythrosome obtained by fusing RBCs with resected tumors 




We engineered RBC membrane vesicles (nanoerythrosomes) by 
fusing ghost RBCs and tumor cell membrane with the desired ratio 
(Fig. 1A). As shown by the transmission electron microscopy (TEM) 
and dynamic light scattering (DLS) analyses, tumor membrane–
fused nanoerythrosomes (nano-Ag@erythrosome) were obtained 
via sonication and physical extrusion (Fig. 1B and figs. S1 and S2). 
Nanoerythrosomes showed rapid clearance from the blood into the 
spleen upon systemic administration via intravenous injection, 
making them an effective vehicle for the targeted spleen delivery. 
SDS–polyacrylamide gel electrophoresis (SDS-PAGE) was performed 
to verify antigen load on nano-Ag@erythrosome. Compared to the 
tumor cell membranes or nanoerythrosomes, nano-Ag@erythrosome 
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contained both proteins from RBCs and tumor cell membranes 
(Fig. 1C). Melanoma expresses glycoprotein 100 (gp100), which is 
a melanoma tumor–associated antigen that can induce cytotoxic 
T cells (34). To prove the fusion of RBC membranes, immuno-
precipitation was performed before Western blot analysis. Band 3 
anion transport protein is a key protein present on the erythrocyte 
surface. After immunoprecipitation with anti–Band-3 beads, a strong 
gp100 signal was observed on pull-down protein of nano-Ag@
erythrosome (Fig. 1D and fig. S3). Nano-Ag@erythrosomes were 
incubated with DCs, and confocal microscopy imaging showed 
effective DC uptake of nano-Ag@erythrosome. Colocalization of 
fluorescent signals was observed from nano-Ag@erythrosome 
compared with a simple mixture of nanoerythrosomes (labeled with 
DiD) and tumor vehicles (labeled with DiL) (Fig. 1E). In addition, 
the CD80 and CD86 expression of bone marrow–derived DCs was 
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Fig. 1. Schematic and characterization of nano-Ag@erythrosomes. (A) Schematic of preparation of nano-Ag@erythrosomes by fusing tumor antigen–associated cell 
membrane into nanoerythrosomes. (B) Representative TEM image of nano-Ag@erythrosomes. Scale bar, 250 nm. (C) SDS-PAGE pattern of proteins from (1) marker, (2) 
nano-Ag@erythrosomes, (3) B16F10 cell membrane, and (4) RBC cell membrane. (D) Western blot result of gp100 on various groups after immunoprecipitation with anti–
Band-3. Equal quantities of protein from each sample were subjected to SDS-PAGE and immunoblotting with gp100-specific monoclonal antibody (Ab). Western blot 
showed that the tumor antigen gp100 was fused into nano-Ag@erythrosomes. (E) Confocal laser scanning microscopy images of mouse bone marrow–derived DCs 
treated with nano-Ag@erythrosomes for 2 hours. A mixture of RBC and B16F10 membranes was used as control. Scale bars, 5 m (left) and 2 m (right). (F) Representative 
flow cytometric analysis of maturation of mouse bone marrow–derived DCs treated in vitro with nano-Ag@erythrosomes for 12 hours and (G) corresponding quantifica-
tion results (n = 3). Data are means ± SEM. Statistical significance was calculated by Student’s t-test. *P < 0.05.
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F and G). Collectively, these results show that the fused nanoerythro-
somes and tumor cell membrane antigen could be formed as expected.
To evaluate the effect of nano-Ag@erythrosome on in vivo targeting 
of APCs, we varied RBC membrane–to–tumor cell membrane (R:T) 
ratios based on the protein weight. We observed that the size and 
 potential of hybrid vehicles were not affected obviously by changing 
the R:T ratios. The fused membrane formed stable nanoparticulate 
vehicles of reproducible size (about 200 nm) and charge (about −10 mV) 
(fig. S1). Tumor cell membranes labeled with Cy5.5 before the fusion 
into nano-Ag@erythrosomes were intravenously administrated into 
mice. We found that the increase of the R:T ratio enhanced the signal 
of tumor antigen in the spleen, but not in the liver and other organs. 
In contrast, at lower R:T ratios, RBC tumor antigen signals had a 
propensity to accumulate in the liver (Fig. 2, A to C, and figs. S4 and S5). 
To better understand the function of the components, RBC and B16 
membranes were labeled with DiD and DiR, respectively, before 
membrane fusion. Nano-Ag@erythrosomes with an R:T ratio of 20:1 
were injected intravenously. While the signal of the RBC membrane in 
the spleen remained almost unchanged, the signal of B16 membranes 
of nano-Ag@erythrosomes was greatly enhanced compared with the 
mixture (fig. S4). Hence, we selected nano-Ag@erythrosomes with 
an R:T ratio of 20:1 for the further studies.
Administration of nano-Ag@erythrosomes up-regulated 
stimulatory and inhibitory markers on splenic DCs 
and macrophages
The spleen, known as the organ consisting of the highest density of 
APCs, plays a central role in the detection and capture of antigens and 
pathogens in the circulation, as well as antigen processing to stimulate 
naïve T cells (23). We have validated that nano-Ag@erythrosomes 
were quickly cleared from the blood into the spleen within 1 hour 
after intravenous administration. Antigens delivered by nano-Ag@
erythrosomes colocalized with major histocompatibility complex 
(MHC) II+ APCs in the spleen, as measured by immunofluorescence 
imaging (Fig. 2D), suggesting effective uptake of the antigen by APCs. 
We have further analyzed various stimulatory and inhibitory molecules 
expressed on the splenic macrophages and DCs after the nano-Ag@
erythrosome treatment. Nano-Ag@erythrosomes were labeled 
with DiD before injection. According to the flow cytometry results, 
the expression of various stimulatory markers including CD80, CD86, 
CD40, and MHC II on splenic DCs and macrophages was up-regulated 
after mice were treated with nano-Ag@erythrosome. Compared 
with DCs and macrophages without nano-Ag@erythrosome uptake, 
cell populations that internalized nano-Ag@erythrosome expressed 
higher stimulatory markers. Notably, the inhibitory molecule PD-L1 
expression on DCs and macrophages was also enhanced after admin-
istration of nano-Ag@erythrosome, indicating that blockade of 
PD-L1 on splenic APCs in combination with nano-Ag@erythrosomes 
could induce potential synergetic antitumor effect (Fig. 2, E and F, 
and fig. S6).
Notably, splenic NK cells, B cells, CD4+ T cells, and CD8+ T cells 
were also activated by nano-Ag@erythrosomes (Fig. 2, G and H). 
Systemic cytokines in the serum were analyzed during the treatment. 
We analyzed 13 kinds of cytokines in the serum. Of note, all the 
cytokine levels were found elevated after 24-hour Ag@erythrosome 
injection, but their levels were decreased after 48 hours. All these 
cytokines were produced by the activated T cells, B cells, NK cells, DCs, 
and macrophages (Fig. 2I and fig. S7). For example, type I interferons 
(IFNs) are mainly produced by APCs in response to antigens. DCs and 
macrophages also produce some proinflammatory cytokines for an 
efficient inflammatory environment (35, 36). Besides, we also observed 
some cytokines released by activated T helper 1 (TH1) cells and NK 
cells. Cytokines such as IFN- (37) were increased after the 24-hour 
nano-Ag@erythrosome injection (Fig. 2I). Together, these results 
suggest that the Ag@erythrosome treatment effectively activated 
various immune cells.
Therapeutic efficacy of nano-Ag@erythrosomes 
in combination with PD-L1 blockade
We have further tested the therapeutic efficacy of nano-Ag@erythrosomes 
in tumor-bearing C57BL/6 mice. In the B16F10-Luc tumor model, mice 
received three doses of nano-Ag@erythrosomes with or without aPDL1 
(Fig. 3A). While tumor growth was not affected by nano-Ag@erythrosome 
vaccine alone (Fig. 3, B and C), the combination with aPDL1 was 
effective (Fig. 3, B and C). Forty-four percent of the mice treated 
with nano-Ag@erythrosomes and aPDL1 survived 40 days (Fig. 3D), 
without notable changes in body weight (Fig. 3E). In addition, the 
fraction of the RBC membrane in nano-Ag@erythrosome could 
benefit the therapeutic efficacy compared to the B16F10 membrane 
alone (fig. S8), which was probably due to the insufficient spleen 
accumulation of B16F10 membrane vesicles. The antitumor effects 
were corroborated by T cell responses, as evidenced by the higher 
percentage of tumor-infiltrating lymphocytes (TILs) (Fig. 3, F and G) 
that produce IFN- (Fig. 3, J and K). As IFN- can up-regulate PD-L1 
expression in tumor cells (38), we examined the PD-L1 expression 
on nonhematopoietic cells (CD45− cells) and found that the tumor 
has a lower PD-L1 expression on CD45− cells when combined with 
aPDL1 therapy, indicating that the inhibition of PD-L1 mediated 
T cell exhaustion in the tumor microenvironment (Fig. 3, H and I). 
The antitumor activity of combining nano-Ag@erythrosomes and 
aPDL1 was conformed in a lung B16F10-Luc and 4T1-Luc metastatic 
tumor model (figs. S9 and S10). Collectively, these results suggested that 
the anticancer immune response induced by nano-Ag@erythrosomes 
was amplified by aPDL1 treatment.
In cancer patients, personalized cancer vaccines may be vitally 
important, as genetic mutations of every individual patient lead to 
the expression of unique tumor antigens known as neoantigens (39). 
As malignant tumors grow, unique tumor neoantigens may be 
expressed. In addition, tumor cells express a whole array of TAAs, 
which is a good source of numbers of different tumor antigens (40). 
We therefore also implemented a model to assess whether the 
developed approach could inhibit recurrence and metastatic spread 
of the tumor after resection of the primary tumor (Fig. 4A). In 
B16F10-Luc tumor-bearing mice cells, tumor was surgically resected 
at day 7. Single-cell suspension from the removed tumor was obtained, 
and RBCs were collected from the same tumor-bearing mice to generate 
an autologous nano-Ag@erythrosomes. Mice were then inculcated 
in the opposite flank with B16F10-Luc tumor cells (Fig. 4B), and at 
day 0, treated with autologous nano-Ag@erythrosomes and aPDL1. 
As shown in Fig. 4, C to E, nano-Ag@erythrosomes and aPDL1 
treatment controlled the growth of the secondary tumor and extended 
survival after surgery, without notable side effects as compared to 
the control group (Fig. 4F).
DISCUSSION
In the current study, we reported an antigen delivery system based 
on the erythrocyte membrane vehicle, nanoerythrosomes extruded 
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Fig. 2. Nano-Ag@erythrosomes target the splenic APC and induce activation of immune cells. (A) Fluorescence imaging of C57BL/6 mice (n = 3) 1 hour after intravenous 
injection of nano-Ag@erythrosomes at various ratios. (B to D) Ex vivo imaging of spleen 1 hour after intravenous injection of nano-Ag@erythrosomes at various ratios (B) 
and corresponding quantification results (n = 3) (C). (D) Confocal images of splenic localization of MHC II+ and Cy5.5 double-positive cells in C57BL/6 mice (n = 3) 1 hour 
after intravenous injection of Cy5.5-labeled nano-Ag@erythrosomes. (Upper left: Splenocyte of mice in 1:0 group. Bottom left: Splenocyte of mice in 1:20 group.) Scale 
bars, 50 m (left) and 10 m (right). (E) Flow cytometric analysis of various activation markers and PD-L1 in DCs (gated on CD11c+) in spleen of untreated mice and mice 
treated with DiD-labeled nano-Ag@erythrosome and (F) corresponding quantification of mean fluorescence intensity (MFI) according to (E). ns, not significant. (G) Activation 
markers measured 24 hours after intravenous injection of nano-Ag@erythrosomes in splenic immune cell subsets (red for treatment, gray for control). (H) Corresponding 
quantification of MFI according to (G) (n = 5). (I) Cytokines level in serum 24 and 48 hours after intravenous injection of nano-Ag@erythrosomes. For (F) and (H), data are 
means ± SD. Statistical significance was calculated by Student’s t-test. For (C) and (I), data are means ± SEM. Statistical significance was calculated by one-way ANOVA with 
Tukey’s post hoc test. *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.001.
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from RBCs, in combination with aPDL1 for combined cancer immuno-
therapy. Compared with other antigen delivery systems, the RBC- 
derived formulation could achieve competitive safety profiles. 
Meanwhile, tumor antigens were loaded onto the nanoerythrosomes 
by fusion of tumor cell membrane–associated tumor antigens with 
nanoerythrosomes, without any chemical reactions or chemical 
linkers. Therefore, it could be metabolized in the biological system 
without any unwanted by-products. As senescent or damaged RBCs 
are the targets of the macrophages and DCs of the spleen, the nano-
erythrosomes have the inherent capacity to be captured by these 
two main APCs in our body. We have demonstrated that APCs 
could be targeted effectively in vivo via intravenously administered 
nano-Ag@erythrosomes when the R:T ratio is 20:1.
We have observed a significant activation of immune system by 
a single dose of nano-Ag@erythrosome administration. Unlike RBCs, 
the nanoscaled nano-Ag@erythrosomes may serve as adjuvants, 
promoting APC activation and maturation. One possible reason is that 
the inside-out structure of cell membrane vesicles is different from 
RBC (41). These outside-out structure vesicles might be recognized 
by splenic DCs for the missing self-markers including CD47. In 



































































































































































































































































Fig. 3. Combination immunotherapy for inhibition of B16F10-Luc melanoma growth in vivo. (A) Schematic representation of the B16F10-Luc tumor model. s.c., subcutaneously; 
i.v., intravenously. (B and C) Individual (B) and average (C) tumor growth kinetics in control and treated groups (n = 7 to 10). Growth curves represent means ± SEM; growth curves were 
stopped when the first animal of the corresponding group died. Animals were euthanized when  exhibiting signs of impaired health or when the volume of the tumor exceeded 1.5 cm3. 
(D) Survival curves for the treated and control mice. (E) Body weight of mice after different treatments as indicated. (F) Representative dot plots showing the number of CD4+ and CD8+
T cells as a percentage of the total CD45+ cell population in the tumor after different treatments as indicated and (G) corresponding quantification results (n ≥ 4). (H) Flow cytometric
analysis of PD-L1 expression in tumor (gated on CD45−) after different treatments as indicated and (I) corresponding quantification results (n = 3). (J) Flow cytometric analysis of the percentage
of intracellular IFN-+ CD8+ T cells in tumor after different treatments as indicated and (K) corresponding quantification results (n ≥ 4). Data are means ± SEM. For (D), statistical significance
was calculated by Log-rank (Mantel-Cox) test. For (I), (G) and (K), statistical significance was calculated by one-way ANOVA with Tukey’s post hoc test. *P < 0.05; **P < 0.01. ***P < 0.005.
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addition to macrophages and DCs, NK cells, B cells, and CD4+ and 
CD8+ T cells were also effectively activated, and a transient boost 
of serum cytokines produced by TH1 and NK cells occurred after 
administration, indicating that the immune response is being activated 
by the antigens. However, in the mouse tumor model, the induced 
immune response by nano-Ag@erythrosome failed to inhibit the 
tumor growth. We further analyzed the stimulatory and inhibitory 
molecules expressed on the splenic macrophages and dendrite cells 
after the nano-Ag@erythrosome treatment. Both stimulatory (CD80, 
CD86, CD40, and MHC II) and inhibitory (PD-L1) molecules on 
splenic DCs and macrophages had increased expression after treatment. 
A higher PD-L1 expression by DCs stimulates the development of 
regulatory T cell populations, which results in immune tolerance. 
This also explains why nano-Ag@erythrosomes alone showed limited 
antitumor effects in Fig. 3. In addition, the immunosuppressive 
nature of the tumor microenvironment could also hamper the antitumor 
immunity. As expected, blockade of PD-L1 by antibody in combination 
with nano-Ag@erythrosomes induced T cell activation and synergetic 
antitumor effect based on our results. A strong T cell–mediated 
anticancer immune response and a high CD8 T cell infiltration were 
observed in the tumor site. Furthermore, we prepared “personalized 
nano-Ag@erythrosomes” by fusing surgically removed tumors and 
RBCs, which could lead to enhanced treatment outcome.
In summary, we developed a new approach to deliver TAAs 
to splenic DCs using nanoerythrosomes. This strategy could be 
extended to develop a personalized tumor vaccine taking into account 
the importance of TAAs in determining responses to either adoptive 
transfer of TILs or ICB therapy. Furthermore, this erythrosome- 
based platform technology could be integrated with other membrane 
fusing with specific cargos to treat different diseases. In future studies, 
nonmembrane neoantigens could be also delivered by our vaccine 
formulation by chemical modification or loaded inside the platform.
MATERIALS AND METHODS
Cell lines
The mouse melanoma cell line B16F10-Luc and the mouse mammary 
carcinoma cell line 4T1-Luc were obtained from the American Type 
Culture Collection. B16F10-Luc and 4T1-Luc cells were obtained 
from PerkinElmer. The culture medium for B16F10-Luc cells was 
Dulbecco’s modified Eagle’s medium (HyClone) containing 10% 
fetal bovine serum (Invitrogen) and penicillin and streptomycin 


















































































































Fig. 4. Personalized nano-Ag@erythrosomes for inhibition cancer metastasis and recurrence after surgery. (A) Schematic of preparation of personalized nano-Ag@
erythrosomes. (B) Schematic representation of the primary tumor resection and distant tumor model. (C) In vivo bioluminescence imaging of the distant B16F10-Luc tumors 
after different treatments as indicated. (D) Individual and average tumor growth kinetics in control and treated groups (n ≥ 5). Growth curves represent means ± SEM; growth 
curves were stopped when the first animal of the corresponding group died. (E) Survival curves for the treated and control mice. (F) Body weight of mice after different 
treatments as indicated. Data are means ± SEM. For (D), statistical significance was calculated by one-way ANOVA with Tukey’s post hoc test. For (E), statistical significance 
was calculated by Log-rank (Mantel-Cox) test. **P < 0.01.
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(100 U ml−1) (Invitrogen). The culture medium for 4T1-Luc cells was 
RPMI 1640 medium (HyClone) containing 10% fetal bovine serum 
(Invitrogen) and penicillin and streptomycin (100 U ml−1) (Invitrogen). 
Cells were tested every 3 months for potential mycoplasma. Re- 
authentication of cells was not performed after receipt.
Animals
C57BL/6 and Balb/c mice (6 to 10 weeks) were purchased from 
Changzhou Cavens Experimental Animal Co. Ltd. Mice were treated 
under protocols approved by the Institutional Animal Care and Use 
Committee.
Preparation of nano-Ag@erythrosomes
The whole blood was first collected from the orbital sinus of C57 
mice and stored in phosphate-buffered saline (PBS) containing EDTA. 
Then, RBCs were separated from whole blood by centrifugation 
(2000 rpm, 5 min). The RBC membrane was obtained by a previously 
reported hypotonic treatment (42). Briefly, deionized water containing 
EDTA was added into the obtained RBCs, and the mixture was 
shaken gently for 5 min. The mixture was centrifuged at 4000 rpm 
for 10 min, and the supernatant was collected and further centrifuged 
at 14,800 rpm for 20 min at 4°C. Deionized water containing EDTA 
was added to the precipitation at the first step, and the solution 
was sonicated for 10 s, followed by centrifugation at 14,800 rpm 
for 20 min at 4°C. The procedure was repeated twice. The obtained 
RBC membrane was washed twice with deionized water containing 
EDTA to remove the hemoglobin.
To obtain the B16F10 membrane, the cells were suspended with 
homogenization medium [0.25 M sucrose, 1 mM EDTA, 20 mM 
Hepes-NaOH, and protease inhibitor cocktail (pH 7.4)]. The cells 
were sonicated using Selecta Sonopuls for 30 rounds on ice (Ton = 3 s, 
Toff = 7 s). The solution was centrifuged at 4000 rpm for 10 min, and 
the supernatant was collected and further centrifuged at 14,800 rpm 
for 20 min. The obtained B16F10 cell membrane was washed twice 
with PBS.
To obtain cell membrane from tumor tissue, B16F10 or 4T1 tumor 
tissues were collected and cut into pieces, followed by sonication 
using Selecta Sonopuls for 30 rounds on ice (Ton = 3 s, Toff = 7 s). 
For B16F10 tumor, the mixture was centrifuged at 6000 rpm for 
10 min to remove melanin (for 4T1-Luc tumor, this step was skipped), 
and the supernatant was collected and further centrifuged at 14,800 rpm 
for 20 min.
The protein amount in the RBC and B16F10 membranes was 
determined using a BCA kit. The mixture of both membranes was 
sonicated for 15 min until the mixture solution became transparent. 
During this step, ice was added into the sonicator to avoid protein 
denaturation caused by heat. Then, the mixture was gently shaken 
using a dry bath incubator at 37°C for 30 min before extrusion 
through a 400-nm membrane.
Characterization of nano-Ag@erythrosomes
The size and surface  potential of the hybrid membrane vesicle were 
measured by DLS. TEM images were obtained using a TECNAI G2 
F20 transmission electron microscope. The samples were negatively 
stained with sodium phosphotungstate solution.
To conduct the membrane colocalization, the RBC membrane 
was labeled with DiD and the B16F10 membrane was labeled with 
DiL before extrusion. The fused membrane vesicles, as well as the 
mixed individual erythrocyte and tumor membrane vesicles, were 
cocultured with DC 2.4 for 12 hours. Then, the cells were stained 
with 4′,6-diamidino-2-phenylindole (DAPI) and analyzed using a 
confocal microscope.
Immunoprecipitation and Western blot
The immunoprecipitation of B16F10 cell membrane, RBC membrane, 
membrane mixture, and the fused nano-Ag@erythrosome was conducted 
using a protein binding immunoprecipitation kit (abs955, Absin) 
according to the manufacturer’s protocols. The protein amount of 
all the samples was determined using a BCA kit before Western blot. 
For each well, the protein amount was quantified to ~40 g. All the 
samples were first incubated with anti–Band-3 or immunoglobulin G 
(IgG)–bound beads (18566-1-AP, Proteintech). The level of gp100 
enriched on beads was then measured by Western blotting. Electro-
phoresis was conducted on 15% SDS–polyacrylamide gel and transferred 
onto polyvinylidene fluoride membranes (Merck Millipore, USA). 
Then, the samples were incubated with primary antibody of gp100 
(Anti-Melanoma gp100 antibody, ab137078, Abcam), followed by 
horseradish peroxidase–labeled goat anti-rabbit IgG (H+L) (BA1054, 
BOSTER). The protein signals were detected with an enhanced 
chemiluminescence method using an Amersham Imager 600 imaging 
system (General Electric Company, USA).
Flow cytometry
Mice were intravenously injected with DiD-labeled nano-Ag@
erythrosomes (RBC:B16F10 membrane protein, 20:1; B16F10 membrane 
protein, 10 g). After 12 hours, mice were sacrificed and spleen was 
collected into single-cell suspensions. Splenocytes (2 × 106) were 
stained with fluorescein isothiocyanate (FITC)–CD11c, phycoerythrin 
(PE)–CD80, PE-CD86, PE-CD40, PE–MHC II and PE–PD-L1 for 
DC analysis and FITC-F4/80, peridinin chlorophyll protein (PerCP)–
CD11b, PE-CD80, PE-CD86, PE-CD40, PE–MHC II, and PE–PD-L1 
for macrophage analysis. The cells were analyzed using a FACSCalibur 
flow cytometer (BD Biosciences).
The mice were sacrificed at day 12, and tumors were collected and 
cut into pieces. The tumor tissues were homogenized in PBS containing 
1% fetal bovine serum and filtrated through nylon gauze to obtain single- 
cell suspensions. The primary antibodies used for flow cytometry were 
purchased from BioLegend. The stained cells were analyzed with the 
FlowJo software package (version 10.0.7; TreeStar, USA, 2014).
In vivo distribution study
The B16 cells were first stained with DiD before obtaining the B16 
membrane and fusing with the erythrocyte membrane at different 
ratios (1:0, 1:5, and 1:20). The fused membrane vehicles were intra-
venously injected into healthy C57 mice. After 1 hour, the mice were 
sacrificed, and the major organs were collected and imaged using an 
IVIS spectrum imaging system.
In vivo tumor models
The aPDL1 antibody used in vivo was purchased from Bio X Cell 
(clone: 10F.9G2). C57 mice were subcutaneously injected B16F10-
Luc (1 × 106). Mice were weighed and randomly divided into different 
groups (n = 5 to 10). Seven days later, nano-Ag@erythrosomes 
(10 g) and aPDL1 (2 mg/kg) were intravenously injected into mice. 
An IVIS Lumina imaging system (Caliper) was used to monitor the 
bioluminescence signal generated by cancer cells. The tumors were 
also measured with a digital caliper. Tumor volume was calculated 
according to the following formula: width2 × length × 0.5.
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In another model, B16F10-Luc cells (1 × 106) were subcutaneously 
injected on the right flank of C57 mice and grew for 10 days. Then, 
B16-luc cells (1 × 106) were subcutaneously injected on the left flank 
1 day before removing the first tumor by surgery. The cell membrane 
was extracted according to the method described above, the protein 
amount of which was determined with a BCA kit. The cell membrane 
from the tumor and the erythrocyte membrane were fused at a ratio 
of 1:20. For each mouse, 10-g proteins from the cell membrane 
from the tumor were used. Fused membrane vehicle as well as 
aPDL1 (2 mg/kg) were intravenously injected into these mice at 
days 1, 3, and 5 after surgery.
To conduct the metastasis model, 4T1-Luc cells (1 × 106) were 
first injected subcutaneously on Balb/c mice. 4T1-Luc cells (1 × 105) 
suspended in PBS were intravenously injected into these mice 1 day 
before removing the first 4T1-Luc tumor by surgery. The treatment 
at the same dose was repeated as the method described above.
In vivo bioluminescence and imaging
An IVIS spectrum imaging system was used to acquire the bio-
luminescence images at 10 min after intraperitoneal injection of 
d-luciferin (PerkinElmer) in PBS (15 mg ml−1) into the animals
(10 l g−1 body weight). Exposure time was 5 min for the bio-
luminescence imaging.
Statistical analysis
All results are expressed as the mean ± SEM or SD as indicated. One-
way analysis of variance (ANOVA), Student’s t-test and Tukey’s post 
hoc tests were used when more than two groups were compared. 
Statistical differences in survival rate were determined with the log-
rank test. All statistical analyses were performed using the Prism 
software package (Prism 5.0; GraphPad Software, USA, 2007). The 
threshold for statistical significance was P < 0.05.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/10/eaaw6870/DC1
Fig. S1. Particle size and  potential of nano-Ag@erythrosomes at various ratios of RBC to 
B16F10 cell membrane.
Fig. S2. TEM images of RBC vesicles and B16 vesicles.
Fig. S3. Raw Western blot data according to Fig. 1D.
Fig. S4. Signal of B16 and RBC membranes in major organs.
Fig. S5. Ex vivo imaging of major organs after intravenous injection of nano-Ag@erythrosomes.
Fig. S6. Flow cytometric analysis in macrophages in spleen.
Fig. S7. Cytokine production in serum after intravenous injection of nano-Ag@erythrosomes.
Fig. S8. B16F10-Luc tumor growth curve after mice were treated with nano-Ag@erythrosomes 
or B16 membrane vesicle with aPDL1.
Fig. S9. In vivo therapeutic efficacy of nano-Ag@erythrosomes with aPDL1 in a B16F10-Luc 
lung metastasis model.
Fig. S10. In vivo therapeutic efficacy of nano-Ag@erythrosomes with aPDL1 in a 4T1-Luc lung 
metastasis model.
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